NYSE:PFEPharmaceuticals
Pfizer (PFE) Valuation Check After Positive Phase 3 Wins and New Obesity Drug Licensing Deal
Pfizer (PFE) just delivered a one two punch of pipeline news, with positive Phase 3 results in cancer and hemophilia, plus a fresh obesity drug licensing deal, and the stock is starting to reflect that shift.
See our latest analysis for Pfizer.
Those wins are starting to chip away at a gloomy narrative, with Pfizer’s 30 day share price return of 3.15% and 90 day share price return of 8.16% hinting at rebuilding momentum despite a still negative year to date move and a mixed longer term total...